

Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia

Jasmine Healy,¹ Chantal Richer,¹ Mathieu Bourgey,¹ Ekaterini A. Kritikou,¹ and Daniel Sinnett^{1,2}

¹Division of Hematology-Oncology, Sainte-Justine Hospital Research Center, University of Montreal, QC, Canada, and ²Department of Pediatrics, University of Montreal, QC, Canada

Citation: Healy J, Richer C, Bourgey M, Kritikou EA, and Sinnett D. Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia. *Haematologica* 2010;95(9):1608-1611. doi:10.3324/haematol.2010.022459

Online Supplementary Table S1. Summary of primers used in the PCR and allele-specific primer extension (ASPE) assays for SNP genotyping.

Gene (Chr)	DNA variant	Position	PCR primers	Product size (bp)	Allele	TAG-ASPE primers
ARID5B (10q21.2)						
	rs7073837	63.369.901	F: ACCAGAACGACACAGTCTCCTTGC R: GGTCCAGCGTGGAAAGGCCACA	241	A C	TCATTTACCTTAATCCAATACTGGAGAGTGGATCATTCCTCA CTAAATTACCTTTCAATACAATACAGGAGACTGGATCATTTCCCTCC
	rs10994982	63.380.110	F: ACCTCGTGATCTGCCGCC R: CCACCTCGGCCCTCCGGAGT	204	A G	CTAAATTACTAACATCACTAACAACTCATGGTCTTTAAATATCTTTGAGAATGCAA TCAATTACTTCATTTAATCCCTTCATGGTCTTTAAATATCTTTGAGAATGCAG
	rs10740055	63.388.485	F: ACCACTATGCCACTTATCGGAGACAACA R: GCCCGGCCGTGACCTCTTT	278	G T	CAATAAACATACCTCTCACTAACACAGGGTTCTATTGAAAGCTGG CTTAAATCCTTATACCTTATCACACAGGGTTCTATTGAAAGCTGT
	rs10821936	63.393.583	F: ACCAGCTGGCAGAGCATCC R: CCCGGTGCCTGAACACACT	257	C T	TCATAATCTCAACAATCTTCTTCTGTGTGAGTTACTATAGTTGTAC TCATCAATCAATCTTCTTCTGTGTGAGTTACTATAGTTGTAT
	rs7089424	63.422.165	F: TGGCTCCCGGTGCTGGCTTA R: CCCAAAACCAAGGTTGAACCAGC	271	G T	TACACTTCTTCTTCTTCTTCTTGTAGCAGTTGGTTATAGTTAGTTG CAATTTCATCATTCAATTCACTTCAGTAGCAGTTGGTTATAGTTAGTT
IKZF1 (7p12.2)						
	rs6964823	50.234.305	F: CTGCCCCCTGCAGCGTCTGGC R: AGGCCTGGCCGGCTCTCAAG	289	C T	TCATCAATCTTCAATTACTACGACGAATGGCTTCTCTCTTC TTACTTCACTTCTAATTACAATCAGACGAATGGCTTCTCTCTCTT
	rs11978267	50.240.513	F: ACTGGCAAGACTGCGGTGTG R: GCTCTCATGGCACGCTCCCC	298	C T	CAATTCAAACTACAATAATCAATCAGGGGAGGGTAGGTAGAAGTTATGC ATCCTTCTTAAATCTCAAATCACTAGGGGAGGGTAGGTAGAAGTTATGT
	rs4132601	50.244.813	F: GGGTGTGGCATTTGAAACGGGA R: ACCAACTGACTCAGGGGGATGGA	231	G T	TCAAATCTCAAATCAATCAGAGAAAAGATGCGCCTG CAATTAACTACATACAATACATCACAGAGAAAAGATGCGCCTT
	rs6944602	50.247.960	F: ACACAGCTCACGGTGTGACCC R: ATTGCTGCACGGGGTCTGC	184	A G	TACACAACTTTTCAATTACATCACAGGGGATTACACTCA ATCATACATACATACAATCTACACCAGGGGATTACACTCG
DDC (7p12.2)						
	rs7809758	50.347.542	F: TGTCCAGCCCAGCCACCTGT R: CCCCGATTCGAGACCTTGTGGC	180	C T	CTTTATCAATACATACTACAATCAAAGCTGGTAGACGAACCTTC ATACTACATCATAATCAAACATCAAAGCTGGTAGACGAACCTTC
	rs880028	50.344.345	F: ACTTGGCCCAGGGGACAGCA R: TCCTGGCCAGTAGCTGGCTGAT	106	A G	AATCTTACTACAAATCTTCTTGCCTTAAATCCGATAGCCCTA CTTTTCATCAATAATCTTACCTTGCCTTAAATCCGATAGCCCTG
	rs3779084	50.342.944	F: GGGATGCATGGAGCTGTGGC R: CCCCACTGAGGCAGCCTGC	190	A G	CTTTTCAAATCAATACTCAACTTGGCCCATCTAGGAACCAGGCA CTACAAACAAACAAACATTCAAGCCCATCTAGGAACCAGGCG
	rs2242041	50.303.658	F: ACAGCGGTACTTCCCTCCCT R: CTCAGCATCTCTGAAGGTAGTGGGG	99	C G	CTATCTTAAACTACAATCTAACGTCTTATGCTGAGAGCAATGAAATAAC CTAACTAACAAATCTAACGTCTTATGCTGAGAGCAATGAAATAAG
CEBPE (14q11.2)						
	rs2239633	22.658.897	F: TGCTGGCTCCACCTACCCCC R: CTCTGGAGCACCAACGCAGGC	159	A G	TCATTCACAATTCAATTACTCAATAGTCCTAGGAACAAGCTCTACACA CAATTCAATTACCAATTACCAATTAGTCCTAGGAACAAGCTCTACACG
OR2C3 (1q44)						
	rs1881797	244.015.573	TGTGCACAGCATGTGTTGAGATGA GCACTGGACACAGCTCTGCCT	292	C T	CTACTATACATCTTACTACTTGGGTTAGTTCTGAATTCTGCATT TTACCTTATACCTTCTTCTACTGGGTTAGTTCTGAATTCTGCATT

SNP position relative to the UCSC Genome Browser Human May 2004 Assembly (hg17)

Online Supplementary Table S2. Replication analysis in the Quebec Childhood ALL cohort of germline SNPs whose allele frequencies differed between children with ALL and control groups in two genome-wide association studies.

Gene (Chr.)	Risk DNA variant allele	QcALL replication study				GWA1 - Papaemmanuil et al. ¹				GWA2 - Trevino et al. ²				
		RAF	Subgroup	OR (95% CI)	P value	RAF	Subgroup	OR (95% CI)	P value	RAF	Subgroup	OR (95% CI)	P value	
<i>ARID5B (10q21.2)</i>														
rs7073837	A	0.34	B-cell	1.54 (1.21-1.97)	4.2E-04	0.40	NA	1.58 (1.35-1.89)	4.7E-16	NA				
			B-hyperdip	2.10 (1.51-2.93)	9.6E-06			1.59 (1.48-1.71)	1.0E-15	NA				
rs10994982	A	0.48	B-cell	1.55 (1.22-1.97)	3.8E-04	NA				0.47	NA	1.71 (1.43-2.05)	1.2E-09	
			B-hyperdip	1.87 (1.34-2.60)	2.0E-04	NA				B-hyperdip	1.71 (1.19-2.46)	0.0025		
rs10740055	C	0.49	B-cell	1.71 (1.34-2.19)	1.6E-05	0.50	NA	1.53 (1.41-1.64)	5.4E-14	NA				
			B-hyperdip	2.06 (1.46-2.90)	3.0E-05			1.57 (1.45-1.81)	1.6E-14	NA				
rs10821936	C	0.33	B-cell	1.93 (1.51-2.48)	1.7E-07	NA				0.33	NA	2.00 (1.68-2.38)	2.8E-16 ^a	
			B-hyperdip	2.91 (2.08-4.07)	2.0E-10	NA				B-hyperdip	2.12 (1.49-3.01)	9.7E-06		
rs7089424	G	0.43	B-cell	1.91 (1.49-2.45)	3.6E-07	0.34	NA	1.65 (1.54-1.76)	6.7E-19	NA				
			B-hyperdip	2.87 (2.04-4.04)	8.2E-10			1.70 (1.58-1.81)	1.4E-19	NA				
<i>IKZF1 (7p12.2)</i>														
rs6964823	G	0.54	B-cell	1.15 (0.90-1.46)	0.27	0.50	NA	1.52 (1.41-1.64)	6.0E-14	NA				
								1.53 (1.42-1.65)	1.9E-13	NA				
rs11978267	G	0.31	B-cell	1.27 (0.99-1.65)	0.065	NA				0.27	NA	1.69 (1.4-1.9)	8.8E-11	
rs4132601	G	0.31	B-cell	1.26 (0.98-1.62)	0.075	0.28	NA	1.69 (1.58-1.81)	1.2E-19 ^c	NA				
								1.73 (1.61-1.85)	9.3E-20	NA				
rs6944602	A	0.24	B-cell	1.17 (0.89-1.55)	0.27	0.21	NA	1.64 (1.37-2.07)	3.4E-15	NA				
								1.69 (1.56-1.81)	1.5E-15	NA				
<i>DDC (7p12.2)</i>														
rs7809758	G	0.41	B-cell	1.02 (0.80-1.30)	0.9	0.37	NA	1.44 (1.32-1.54)	2.4E-10	NA				
								1.48 (1.37-1.60)	2.9E-11	NA				
rs880028	C	0.25	B-cell	1.04 (0.79-1.36)	0.79	0.22	NA	1.43 (1.30-1.56)	1.3E-07	NA				
rs3779084	C	0.25	B-cell	1.01 (0.77-1.33)	0.92	0.22	NA	1.44 (1.32-1.56)	8.8E-09	NA				
								1.50 (1.37-1.63)	6.5E-10	NA				
rs2242041	G	0.11	B-cell	1.40 (0.99-2.00)	0.059	NA				0.09	NA	1.72 (1.3-2.1)	9.9E-07	
<i>CEBPE (14q11.2)</i>														
rs2239633	G	0.53	B-cell	1.19 (0.94-1.52)	0.15	0.52	NA	1.34 (1.22-1.45)	2.9E-07	NA				
<i>OR2C3 (1q44)</i>														
rs1881797	C	0.17	B-cell	0.95 (0.66-1.35)	0.77	NA	NA				0.16	NA	1.52 (1.2-1.8)	
			t(12;21)	1.31 (0.53-3.24)	0.57						t(12;21)	2.08 (1.1-3.8)	7.3E-06	

Results are shown for allelic case-control association tests; P values in bold remain significant after FDR adjustment for multiple testing at the 5% level. The Quebec Childhood ALL (QcALL) replication cohort consisted of 284 B-cell ALL cases and 270 controls; logistic regression was applied to either the full dataset or to a restricted subgroup of patients as specified. GWA1; the Papaemmanuil et al. study comprised 907 cases (824 B-cell, 83 T-cell) and 2,398 controls; logistic regression was applied to either the full dataset or to a restricted subgroup of patients as specified; P values denote Cochran-Armitage trend test statistics. GWA2; the Trevino et al. study consisted of a discovery cohort of 317 cases (274 B-cell, 43 T-cell) and 17,958 controls; logistic regression was used and subgroup analysis was performed by comparing allele frequencies between single ALL subgroups and all other subgroups combined. Fisher's combined probability method was used to calculate a combined P value of the current QcALL replication study and the previous GWASs. RAF indicates risk allele frequency in controls; OR, odds ratio; CI, confidence interval; B-hyperdip; B-cell hyperdiploid ALL; NA: not applicable. ^aStrongest association signal from the Trevino et al. study. ^bP value denotes case-only logistic regression analysis. ^cStrongest association signal from the Papaemmanuil et al. study.

Online Supplementary Table S3. Distribution of *ARID5B* haplotypes among B-cell ALL cases and controls from the Quebec gender-specific haplotype risks estimates.

Haplotype	DNA variant					B-cell ALL cases	Controls	OR (95% CI)	P value	Global χ^2 (df)	Global P value
	rs7073837	rs10994982	rs10740055	rs10821936	rs7089424	Total (%)					
ARID5B*1	C	G	A	T	T	224 (38.23)	268 (50.00)	1 (referent)	—	45.03 (14)	4.04E-05
ARID5B*2	A	A	C	C	G	271 (46.25)	168 (31.34)	1.93 (1.47-2.53)	7.6E-07		
ARID5B*3	A	A	C	T	T	31 (5.29)	46 (8.58)	0.81 (0.48-1.35)	0.39		
ARID5B*4	C	A	C	T	T	37 (6.31)	34 (6.34)	1.30 (0.77-2.21)	0.30		
ARID5B*	—	—	—	—	—	23 (3.92)	20 (3.73)	1.38 (0.70-2.71)	0.31		
Males (%)											
ARID5B*1	C	G	A	T	T	120 (34.29)	159 (52.65)	1 (referent)	—	36.95 (16)	2.13E-03
ARID5B*2	A	A	C	C	G	170 (48.57)	92 (30.46)	2.45 (1.70-3.52)	3.41E-07		
ARID5B*3	A	A	C	T	T	19 (5.43)	21 (6.95)	1.20 (0.58-2.46)	0.59		
ARID5B*4	C	A	C	T	T	26 (7.43)	15 (4.97)	2.30 (1.11-4.87)	0.014		
ARID5B*	—	—	—	—	—	15 (4.29)	15 (4.97)	1.32 (0.58-3.03)	0.46		
Females (%)											
ARID5B*1	C	G	A	T	T	104 (44.07)	108 (46.35)	1 (referent)	—	21.45 (9)	0.011
ARID5B*2	A	A	C	C	G	99 (41.95)	75 (32.19)	1.37 (0.90-2.09)	0.120		
ARID5B*3	A	A	C	T	T	13 (5.51)	24 (10.30)	0.56 (0.25-1.22)	0.120		
ARID5B*4	C	A	C	T	T	11 (4.66)	20 (8.58)	0.57 (0.23-1.33)	0.16		
ARID5B*	—	—	—	—	—	9 (3.81)	6 (2.58)	1.56 (0.47-5.50)	0.41		

Logistic regression was used to estimate haplotype-specific ORs in either the full dataset or in restricted subgroups stratified by gender comparing male cases to male controls or female cases to female controls. The most common haplotype was used as reference. P values in bold remain significant after FDR adjustment for multiple testing at the 5% level. Percentages indicate number of chromosomes with given haplotype/total number of chromosomes. Haplotypes with relative frequencies <5% are grouped under ARID5B* and are represented as * combinations of the four DNA variants. A likelihood ratio test was performed in FAMHAP to compare global haplotype differences between cases and controls and is reported here as a Global χ^2 test with number of haplotype parameters different from zero-1 degrees of freedom. OR indicates crude odds ratio; df, degrees of freedom; and —, not applicable. *Significant risk difference between males and females based on Mantel-Haenszel χ^2 test of homogeneity: X2= 7.31 (1df); P value= 0.0069.

References

- Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, et al. Loci on
- Trevino LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al. Germline genom-

7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. *Nat Genet.* 2009;41(9):1006-10.

ic variants associated with childhood acute lymphoblastic leukemia. *Nat Genet.* 2009;41(9):1001-5.